ALX Oncology Holdings Inc. Common Stock

Day range

$1.10 – $1.23

Open

$1.17

Prev close

$1.17

Volume

547.5K

Market cap

$164.55M

Shares out

138.28M

P/E

—

P/S

—

P/B

1.21

P/FCF

—

ROE

-59.4%

ROA

-50.3%

Debt/Equity

0.07

Div yield

0.00%

As of Oct 22, 2026

• Board of directorsJun 30, 2026

  On June 29, 2026, Corey Goodman, Ph.D. informed ALX Oncology Holdings Inc. (the "Company") of his resignation as Chairman of the Company's board of directors (the "Board") and as a member of the Board, and from all committees thereof, to be effective as of the close of business on June 29, 2026. Dr. Goodman resigned for personal reasons and not as a result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

• Debt activityJun 26, 2026

  Pursuant to the Agreement, the Borrower borrowed $10,000,000 of loans at closing, the proceeds of which were used to refinance the Borrower's existing loan agreement with Oxford Finance and Silicon Valley Bank and to pay closing fees and expenses. An additional $20,000,000 remains available to draw through June 30, 2028.

• Executive leadershipApr 13, 2026

  Effective April 13, 2026, the Board of Directors (the "Board") of ALX Oncology Holdings Inc. (the "Company") appointed Jeff Knight as Chief Development and Operating Officer. Jeff Knight, age 55, served as the Chief Development and Operating Officer at Crinetics Pharmaceuticals, Inc., a global biopharmaceutical company, from September 2021 to April 2026.

• Equity activityJan 30, 2026

  On January 30, 2026, ALX Oncology Holdings Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Piper Sandler & Co., UBS Securities LLC and Wells Fargo Securities, LLC as representatives of the several underwriters named therein, relating to the issuance and sale (the "Offering") of 76,979,112 shares of the Company's common stock at an offering price of $1.57 per share and pre-funded warrants to purchase 18,574,120 shares of Common Stock at an offering price of $1.569 per Pre-Funded Warrant. The gross proceeds from the Offering are expected to be approximately $150 million before deducting underwriting discounts and commissions.

• Earnings and performanceJan 30, 2026

  On January 30, 2026, the Company disclosed that, based upon preliminary estimates, it had approximately $48.3 million of cash and cash equivalents and short-term and long-term investments as of December 31, 2025. The Company has not yet completed its year-end financial close process for the year ended December 31, 2025. This estimate of the Company's cash and cash equivalents and short-term and long-term investments as of December 31, 2025 is preliminary, has not been audited, does not present all information necessary for an understanding of the Company's financial position as of December 31, 2025, and is subject to change upon completion of its financial statement closing procedures.

Days to cover

3.8

Short interest

5.67M

Avg volume

1.5M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
  positiveGlobeNewswire Inc.· Feb 27, 2026
• ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
  positiveGlobeNewswire Inc.· Jan 8, 2026
• ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
  positiveGlobeNewswire Inc.· Dec 7, 2025
• HER2-positive Gastric Cancer Clinical Trial Pipeline: Insights into a Growing Landscape with 20+ Companies Advancing Novel Treatments| DelveInsight
  positiveGlobeNewswire Inc.· Nov 27, 2025
• ALX Oncology to Present at Upcoming Investor Conferences
  positiveGlobeNewswire Inc.· Nov 18, 2025